Key Highlights
- Dr. Kurt Gish joins BioLoomics as Chief Scientific Officer.
- Focus on building pipeline of lysosomal targeting ADCs in oncology.
- Aims to overcome limitations of poor tumor uptake in ADCs.
- Dr. Gish brings extensive experience from Trilo Therapeutics and AbbVie.
Source: Business Wire
Notable Quotes
- “Kurt is an impressive and accomplished scientist that sits at the intersection of ADCs, peptides, and target discovery/validation. He has a deep understanding of how improper spatial targeting of ADCs has limited the field. With his deep experience in the ADC space, I am confident that Kurt will be invaluable to advancing BioLoomics’s technology to build safer and more efficacious ADCs for both strategic partners and internal programs.” — Dr. Chapnick, CEO and Founder at BioLoomics
- “BioLoomics is developing incredible technology to deliver more therapeutic drug directly into cancer cells while minimizing systemic toxicity. I’m thrilled to join such an innovative team and look forward to getting the best possible treatments to patients that so desperately need them.” — Dr. Kurt Gish, Chief Scientific Officer at BioLoomics
SoHC's Take
The addition of Dr. Kurt Gish as Chief Scientific Officer at BioLoomics marks a significant milestone for the company. Dr. Gish’s extensive experience in antibody-drug conjugates (ADCs) and his innovative approach to lysosomal targeting will be crucial in overcoming the current challenges faced in oncology treatments. His background, particularly from his tenure at Trilo Therapeutics and AbbVie, positions him uniquely to drive BioLoomics’s technology forward, enhancing both safety and efficacy of ADCs. This strategic move underscores BioLoomics’s commitment to pioneering advanced therapeutic solutions and improving patient outcomes in the cancer treatment landscape.
